Some of these therapies are already FDA approved for a specific subset of patients, for example, those affected by NSCLC harboring fusion genes of ROS1 or ALK, while others are still in the phase of transition into clinical practice with effective results in clinical trials. This evidence concerns the gene ALK and non-small cell lung carcinoma.